U.S. Markets closed

Repros Therapeutics Inc. (RPRX)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.3046-0.0054 (-1.7419%)
At close: 4:00PM EDT
People also watch
SNSSOPXATHLDCYCCOGXI
  • D
    David Harrington
    David Harrington
    Haha I love Hiwatt. So predictable! These Abbvie lawsuits have nothing to do with new products nor existing products as labeled. I love ragging on Hiwatt because he loves to fight the old fight because that's all he has left, just memories of times that have all past. Hiwatt still thinks he's "right" and that Repros is still going to "win". Repros doesn't even have the best SERM. $RPRX is the worst disaster company who relied on Joey's special Gay Cubans analysis to keep his story afloat.
  • D
    David Harrington
    David Harrington
    From doofus Hiwatt, the $RPRX moron on Joey's little choo choo train that couldn't (ever): "I predicted a couple months back we could hit .30 cents and today we closed at .3085. I also predicted we would go to P3 with Proellex, or go to pinks sheets if decision went south. Well we didn't go to P3 and we have until Sept 30 to avoid pink sheets. In 2010 it took a 1 for 4 reverse split to stay listed. Will history repeat? Anyway here's my post from months back.
    . Yes I'm still long and yes the stock could hit 30 cents like it did in 2009. It now all comes down to FDA guidance on Proellex and I'm betting we go to P3 . It's possible an EU approval could help longs get back their losses, but if Proellex decision goes south, we'll be trading on pink sheets until that vote comes down."
  • D
    David Harrington
    David Harrington
    $RPRX failed where APRICUS will win. I think the resubmission too looks promising but I haven't given up on APRI SERM story.
  • E
    Emma
    Emma
    hey now! I love RPRX and all but it has been pretty slow latley. Check out thestock-dork for some better plays. .
  • f
    flow
    flow
    Rprx is getting ready to est that .36/37 level.Break that on volume and test of the 50 dma is coming.Break that with volume and you MOVE INTO THE GAP baby. Could be a monster spike
  • P
    Pharmaheroooooo
    Pharmaheroooooo

    SNOA (MC $23 M) (Cash $13 M) Shares Out: 4.3 M /Undiscovered Stock/ Lots of Marketed Products some of them are in early launch phase plus additional Product launches expected within 6 months / Profitable in 2018 = 1000%+ UPSIDE POTENTIAL..Please do your own dd and realize the Monster Potential here .Thank me later

    Sonoma Pharma (Nasdaq: SNOA)

    Market Cap: 22.1 Million
    Cash: $12.6 Million
    Price: $5.15

    Shares Out : 4.3 Million

    Presentation
    http://ir.sonomapharma.com/common/download/download.cfm?companyid=ocls&fileid=945547&filekey=F57B6874-6CD1-4205-A160-8E08BBB7A928&filename=SonomaPharma_Investor_presentation_13June2017.pdf

    Fact Sheet
    http://files.shareholder.com/downloads/OCLS/4977255852x0x231236/39d834a3-8462-40ee-8650-e0945b6facd5/Sonoma_Fact_Sheet.pdf

    Driving to commercial EBITDAS breakeven, without dilution

    Grow current product portfolio with all sales people

    •Alevicyn HydroGel, Dermal Spray & Spray Gel for atopic dermatitis & dermal procedures •Celacyn for scar treatment
    •Mondoxyne for severe acne –launched late 2015
    •Ceramax for skin repair in atopic dermatitis–launched in April 2016
    •SebuDerm for seborrhea dermatitis –launched in November 2016

    Launch 3 New Products –our product pipeline –one every other quarter

    •Launching Loyon–Fall 2017
    •Ceramax in foam and gel forms –Q4 2017 & Q1 2018

    Launch and Grow New and Current Products: During fiscal year 2017, we launched four new dermatology products, including SebuDerm™, Ceramax™, Lasercyn™ Gel and Lasercyn™ Dermal Spray, bringing us to a total of eight dermatology products for the treatment of atopic and seborrheic dermatitis, scar management, surgical procedures, severe acne and “state of the art” skin repair technology. We also obtained three new FDA clearances, now totaling 16 overall. Our strong intellectual property portfolio consists of 63 issued patents and 33 patent applications pending.

    We plan to launch our new FDA approved product Loyon® (a skin descaler currently marketed in Europe) in the upcoming months and have a strong product pipeline of several product line improvements, including a line extension of Ceramax™. All in all, we believe this could possibly be our best product line of new FDA approved dermatology and skincare products yet, and we believe our innovation plan will help lead us to profitability.

  • z
    zhead9401
    zhead9401
    The last POS biotech stock I'll ever invest in.
  • R
    Robert
    Robert
    potn making 1.4 million a month at .05 a share is a steal
  • h
    hiwatt1959
    hiwatt1959
    A little more insight on Proellex V from a patent published in Jan of 2017.

    Cumulatively, the data indicate that a four-fold lower dose of antiprogestin can be administered vaginally compared to the effective dose when orally administered, while attaining only a small fraction of the maximal circulating concentrations compared to oral administration, thereby avoiding liver toxicity. For example, equivalent antiprogestational activity at the uterus is observed for a 50 mg oral dose of CDB-4124 and a 12.5 mg vaginal dose; however, the Cmax observed with a 12.5 mg vaginal dose is only 2% that observed with a 50 mg oral dose. The relatively high local concentration of the drug achieved by local administration allows a relatively low dose of the drug (compared with oral administration) to achieve therapeutic effect for indications localized to the pelvic and reproductive tract (e.g. endometriosis, uterine fibroids and ovarian cancer). Because a high concentration of the drug in the systemic circulation (and associated first pass metabolism of the drug) is not reached by local administration, avoidance of the severe liver toxicity observed in a small percentage of subjects following oral administration of CDB-4124 in previous Phase III clinical studies at doses of 25 and 50 mg is a surprising advantage of administering the drug locally. Similar advantages should inure to local administration of other antiprogestins.

    Example 6
    Vaginal Administration of CDB-4124 for the Treatment of Uterine Fibroids
    Seven human females with uterine fibroids have completed 4 months of treatment as part of a single blind study. These females were vaginally administered a daily dose of 12 mg CDB-4124 for a period of four months, with dosing initiated during the luteal phase of the females' menstrual cycles. At the end of the four month treatment period, all seven females stopped menstruating and all reported a Pictural Blood Loss Assessment Chart (PBAC) score of 0 (p=0.002). A statistically significant and highly clinically meaningful reduction in Uterine Fibroid Symptom Quality of Life Survey (UFSQOL) scores was also observed. The mean UFSQOL score at baseline was 43.8 and at the end of the four month treatment period the mean score was 1.33 (p=0.001). Both bleeding and bulk related symptoms assessed by the UFSQOL were dramatically reduced with six of the seven females responding that they no longer experienced any fibroid related symptoms. As a reference, women with fibroids typically score 40 or higher, whereas women without fibroids report scores of approximately 20.

    Change in fibroid volume at the end of the four month treatment period determined by magnetic resonance imagining (MRI) was assessed and a statistically significant (chi square analysis) median reduction of total fibroid volume of 36% was observed.

    In an oral study, doses of 1, 3, 6, 9 and 12 mg of CDB-4124 were administered for a period of 10 weeks. In the oral study, all doses were well tolerated and reliable cessation of menses was induced at doses as low as 3 mg. Cessation of menses directly correlated to efficacy of an oral dose in both uterine fibroids and endometriosis. Pharmacokinetic analysis revealed that vaginal administration of 12 mg of CDB-4124 resulted in about ⅙th the systemic exposure of an equivalent oral dose based on area under the curve (AUC) and a maximum exposure (Cmax) about 1/100th of a 50 mg oral dose.

    The concentration of CDB-4124 was observed to build slowly when the drug is vaginally administered relative to oral administration. Thus, the onset of amenorrhea is delayed when the drug is administered vaginally, necessitating that the drug be vaginally administered during subsequent menstruations, which tends to reduce absorption of the drug and is unpleasant and technically challenging for the patient. The methods of the present invention provide a solution to this problem by providing a brief period of oral administration, preceding and overlapping vaginal administration, which expedites the onset of amenorrhea while retaining the benefits of vaginal administration.
  • H
    HZ
    HZ
    Anyone know when is the EU patent going to have news?
  • h
    hiwatt1959
    hiwatt1959
    I predicted a couple months back we could hit .30 cents and today we closed at .3085. I also predicted we would go to P3 with Proellex, or go to pinks sheets if decision went south. Well we didn't go to P3 and we have until Sept 30 to avoid pink sheets. In 2010 it took a 1 for 4 reverse split to stay listed. Will history repeat? Anyway here's my post from months back.
    . Yes I'm still long and yes the stock could hit 30 cents like it did in 2009. It now all comes down to FDA guidance on Proellex and I'm betting we go to P3 . It's possible an EU approval could help longs get back their losses, but if Proellex decision goes south, we'll be trading on pink sheets until that vote comes down.
  • D
    David Harrington
    David Harrington
    Looks like the corrupt crackpot legacy of Joey the Dogdoltski reigns with $RPRX latest failure! Pretty remarkable that investors put up with his obvious misleading of investors with his fake and faulty data. The problems continue for Repros. You just cannot undo years of mismanaged studies and negligence. Proellex will never get out of phase 2 ever. Too many safety problems ignored.
  • h
    hiwatt1959
    hiwatt1959
    Sperm concentrations drop over 50% in the last 40 years. If only there was a drug that enhanced testosterone levels and maintained sperm counts. Hmmm.

    The quality of sperm from men in North America, Europe and Australia has declined dramatically over the past 40 years, with a 52.4 percent drop in sperm concentration, according to a study published Tuesday.

    The research — the largest and most comprehensive look at the topic, involving data from 185 studies and 42,000 men around the world between 1973 and 2011 — appears to confirm fears that male reproductive health may be declining.

    The state of male fertility has been one of the most hotly debated subjects in medical science in recent years. While a number of previous studies found that sperm counts and quality have been falling, some dismissed or criticized the studies over factors such as the age of the men included, the size of the study, bias in counting systems or other aspects of the methodologies.

    Some of the other concerns are outlined in an analysis published by the American Society of Andrology, which focuses on the male reproductive system. The skepticism also has to do with the difficulty of comparing records from a fertility center in the 1970s with one from today and with the fact a single man's sperm count may fluctuate during his life span due to his weight, use of alcohol and many other factors.

    However, Shanna H. Swan, one of the authors of the new study published in the Human Reproduction Update, said that the new meta-analysis is so broad and comprehensive, involving all the relevant research published in English, that she hoped it would put some of the uncertainty to rest. Then the scientific community could move forward into putting its resources into figuring out the why of what is going on, she said.

    “It shows the decline is strong and that the decline is continuing,” Swan said in an interview.

    The analysis found drops only for men in Europe, North America and Australia and not for those in South America, Asia and Africa. Swan explained that this could mean that there's something specific to certain cultures or regions that affects sperm, but that it's also possible that there just isn't enough data yet to draw firm conclusions about the rest of the world. There have been far fewer sperm studies conducted in non-Western countries. (Some of the most recent ones have also noted a decline in aspects of sperm quality. A study published earlier this year about China's Hunan province found that 56 percent of sperm donations met the criteria for health in 2001 vs. only 18 percent in 2015.)
  • M
    Mel
    Mel

    MicroCap Alert to RPRX shareholders. Why Clean Energy Technologies (CETY) shares moved up recently and why they are about to rise sharply again. CETY purchased their Heat Recovery Systems from General Electric.
    Each system sells for about $300,000. Demand for CETY HRS is very strong.
    CETY just expanded Europe sales and service office in high demand market
    CETY immediately announced first new sale in Europe
    CETY presenting to 26 Power Companies in the Pacific on July 31st to August 4th – These 26 power companies need CETY HRS to produce power cheaper and make more profits.

    Expect substantial sales orders to flow soon after conference
    CETY 1017 target: $.15 to $.20

    http://www.prnewswire.com/news-releases/clean-energy-technologies-inc-delivering-low-cost-emission-free-power-with-its-heat-recovery-solutions-clean-cycle-generator-acquired-from-general-electric-international-inc-300228398.html

    https://www.ppa.org.fj/26th-annual-ppa-conference/

    Clean Energy Technologies, Inc. Delivering Low Cost, Emission Free Power with its Heat Recovery Solutions Clean Cycle™ Generator acquired from General Electric International, Inc.
    COSTA MESA, Calif., March 1, 2016 /PRNewswire/ -- Clean Energy Technologies, Inc. (OTC: CETY), recently...
    www.prnewswire.com
  • P
    Peter
    Peter
    is Proellex done completely or just shelved because they won't have the money to continue the larger scale trial? If it was so bad why with a larger trial pool? let poison more people? I don't get it. I don't think it's to bad or they wouldn't ask for a larger pool, it's just the red tape. they need to get something to market quickly so the stop bleeding money and can get back to the oral doses later I guess! I believe in the science behind it.
  • h
    hiwatt1959
    hiwatt1959

    Rosalind Capital becomes our newest, biggest shareholder.
    http://www.conferencecalltranscripts.org/13G/summary2/?id=3983896

    Conference Call Transcripts
    Company Conference Call Transcripts
    www.conferencecalltranscripts.org
  • A
    Anonymous
    Anonymous

    KTOV = Mcap $16 Mil /Cash $17 Mil / ULTRA Low float O/S 10.6 M / NDA submission for potential Blockbuster this Quarter = 20 BAGGER ..ONE OF THE BIGGEST BIOTECH OPPORTUNITY EVER ! Thank me later guys

    Kitov Pharma (KTOV)

    Market Cap: $17 M
    Cash $17 M
    Price: $1.50

    Shares Out: 10.6 Million

    Kitov Pharmaceuticals Initiates NDA Filing for KIT-302 as a Treatment for Osteoarthritis and Hypertension
    https://baystreet.ca/articles/research_reports/lifesci/Kitov062717.pdf

    Kitov Expects to Submit an NDA for KIT-302 in the Third Quarter 2017.Kitov announced that it began the process of compiling the documents necessary to file an NDA for its lead asset KIT-302 as a treatment for patients who experience both osteoarthritis and hypertension. The Company hired Parexel International Corporation, a clinical research organization, to digitalize and formally submit its NDA application. Kitov expects the filing to occur during the third quarter of 2017, with a potential FDA approval during the second quarter of 2018.

    KIT-302 is a combination drug that treats osteoarthritis pain and hypertension simultaneously

    Primary efficacy endpoint achieved Lead drug candidate KIT-302 achieved its primary efficacy endpoint in a pivotal Phase III trial

    Marketing potential Pipeline candidates address large, multi-billion dollar markets

    Products

    Kitov’s current pipeline products, KIT-301 and KIT-302, are combination drugs that treat OA pain and HTN simultaneously. In December 2015, KIT-302 successfully achieved the primary efficacy endpoint for its Phase III clinical trial. In August 2016, the United States Patent Office issued a patent covering KIT-302.

    Market

    Of the 27 million Americans with OA, 50% also suffer from HTN, which is also a common side effect of stand-alone OA drugs. With no single medication currently treating both conditions, KIT-301 and KIT-302 are targeting this multi-billion dollar market.

  • N
    Nat
    Nat
    They got a patent, switched focus to vaginal delivery, and have pending EMA decision approaching. Sounds good
  • D
    Donn
    Donn
    Somebody got a standing order to buy at 38.5 cents. This stock is worth a minimum of 1.25 today. The recent funding dictates this price as they paid for the common share .40 plus .60 for two warrants to purchase more stock at .82 and .94 or somewhere for like a half a share and 3/4 share respectively. Which means to me they value the company some where between 1 dollar and 1.25 a share as of today.
  • e
    ed
    ed
    so the waiting continues? being all in at .45- took all my gains and then some, but if the AH price carries through to tmoro won't be such a terrible loss. august 2nd should put it back in the .50' s .
    still think this is a can't lose price right now. I'm holding!!!